Tag: ObesityTreatment

Novo Nordisk’s once-weekly semaglutide 2.4 mg (Wegovy) demonstrated remarkable liver-health improvements in metabolic dysfunction-associated steatohepatitis (MASH) patients—even those with minimal weight loss—signalling a potential paradigm shift in the obesity-related liver-disease market.